Developer docs
API playgroundTry for free, no card

Search company profiles

Next Generation Gene Therapeutics

Full company profile

uuid0002fh8

Namestring
Next Generation Gene Therapeutics
Legal namestring
NGGT Inc.
Websiteurl
nggtbio.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWalnut Creek, United States
HQ citystring
Walnut Creek
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, rare disease therapeutics, AAV vector manufacturing, clinical-stage biotechnology, rAAV gene therapies
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Revenue
TypeOne Time License
Description

Pre-commercial clinical-stage biotech. Revenue will come from commercializing gene therapy products upon regulatory approval. Currently in Phase I/II clinical trials for NGGT001 (Bietti's Crystalline Dystrophy), NGGT002 (Phenylketonuria), and NGGT006 (Familial Hypercholesterolemia).

nggtbio.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Potential for licensing agreements and partnerships with pharmaceutical companies for co-development or commercialization rights to pipeline candidates.

nggtbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Next Generation Gene Therapeutics (NGGT) is a clinical-stage biotechnology company that discovers, develops, and manufactures investigational recombinant adeno-associated virus (rAAV) gene therapies for rare genetic diseases, using its proprietary dual-functional vector platform. Its current pipeline consists of three investigational gene therapy drug products — NGGT001 for Bietti's Crystalline Dystrophy, NGGT002 for Phenylketonuria, and NGGT006 for Familial Hypercholesterolemia — produced at its 90,000-square-foot cGMP facility in Suzhou, China. NGGT is pre-commercial and monetizes through future product sales, licensing, and pharmaceutical partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Visual acuity improved by 12.8 ± 3.7 ETDRS letters at 9 months in BCD patients (P = .0026)
+3 more records
Product overview1 text field

Next Generation Gene Therapeutics (NGGT) is a clinical-stage biotechnology company pioneering dual-functional vector gene therapies for genetic rare diseases. The company operates its proprietary 'One target, two bullets' technology platform, which uses dual-functional vectors to simultaneously silence harmful mutated genes and express correct protein versions. NGGT's product portfolio includes three clinical-stage gene therapy candidates: NGGT001 for Bietti's Crystalline Dystrophy (Phase I/II), NGGT002 for Phenylketonuria (Phase I/II), and NGGT006 for Familial Hypercholesterolemia (IND-enabling). The company maintains a 90,000-square-foot cGMP manufacturing facility for rAAV production.

Product and service3 records
1NGGT001
CategoryInvestigational gene therapy drug
Description

Investigational AAV2-based gene therapy for Bietti's Crystalline Dystrophy (BCD), a rare autosomal recessive ocular disease caused by CYP4V2 gene mutations, currently in Phase I/II clinical trial. Designed for patients with BCD for whom no approved treatments exist.

2NGGT002
CategoryInvestigational gene therapy drug
Description

Investigational gene therapy for Phenylketonuria (PKU), a rare genetic metabolic disorder caused by deficiency in phenylalanine hydroxylase, currently in Phase I/II clinical trial with demonstrated sustained plasma phenylalanine reduction. Aims to offer a single-treatment alternative to lifelong dietary management.

3NGGT006
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage gene therapy company developing treatments for cancer and diabetes using novel delivery systems. Comparable as a small clinical-stage biotech in gene therapy, though focused on different indications.

TypeBroad incumbent
Description

Established rare disease biotech with a commercialized AAV gene therapy (Roctavian for hemophilia A) and active programs in PKU and other inherited metabolic disorders. Comparable as a larger player in the same gene therapy + rare disease space.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for ocular and rare diseases. Comparable on AAV platform, ocular disease focus (overlap with NGGT001 BCD), and clinical-stage status.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for neurological and rare diseases using proprietary capsid engineering. Comparable on AAV platform and clinical-stage pipeline.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare genetic diseases. Comparable on AAV vector platform and clinical-stage status targeting rare monogenic disorders.

TypeRegional player
Description

China-headquartered clinical-stage biotech with a pipeline spanning oncology and rare diseases, including gene therapy programs. Comparable as a similarly-staged China-US biotech with rare disease ambitions.

TypeDirect peer
Description

Clinical-stage gene therapy company using proprietary AAV vectors (NAV Technology Platform) to treat rare diseases including metabolic and ocular disorders. Most directly comparable to NGGT on AAV platform technology and rare disease focus.

TypeDirect peer
Description

Gene therapy company developing AAV-based treatments for rare diseases including Huntington's disease and hemophilia. Comparable on AAV platform, rare disease strategy, and clinical-stage gene therapy pipeline.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare diseases including ocular and metabolic disorders. Comparable platform technology and rare disease therapeutic focus.

TypeDirect peer
Description

Commercial-stage gene therapy company with FDA-approved Vyjuvek for dystrophic epidermolysis bullosa, using a topical redosable gene therapy platform. Comparable on rare disease gene therapy focus and integrated manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Next Generation Gene Therapeutics

Gene Therapy Pharmaceuticalsnggtbio.com

Next Generation Gene Therapeutics firmographics

Firmographics
Name
Next Generation Gene Therapeutics
Legal name
NGGT Inc.
Website
https://nggtbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Next Generation Gene Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Rare disease therapeutics
  • AAV vector manufacturing
  • Clinical-stage biotechnology
  • RAAV gene therapies

Where Next Generation Gene Therapeutics is headquartered

Location

Headquarters

HQ city
Walnut Creek
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Next Generation Gene Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Product Revenue: Pre-commercial clinical-stage biotech. Revenue will come from commercializing gene therapy products upon regulatory approval. Currently in Phase I/II clinical trials for NGGT001 (Bietti's Crystalline Dystrophy), NGGT002 (Phenylketonuria), and NGGT006 (Familial Hypercholesterolemia).
  2. Licensing and Partnership Revenue: Potential for licensing agreements and partnerships with pharmaceutical companies for co-development or commercialization rights to pipeline candidates.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Next Generation Gene Therapeutics product offering

Product offering

Core offering

Next Generation Gene Therapeutics (NGGT) is a clinical-stage biotechnology company that discovers, develops, and manufactures investigational recombinant adeno-associated virus (rAAV) gene therapies for rare genetic diseases, using its proprietary dual-functional vector platform. Its current pipeline consists of three investigational gene therapy drug products — NGGT001 for Bietti's Crystalline Dystrophy, NGGT002 for Phenylketonuria, and NGGT006 for Familial Hypercholesterolemia — produced at its 90,000-square-foot cGMP facility in Suzhou, China. NGGT is pre-commercial and monetizes through future product sales, licensing, and pharmaceutical partnerships.

Product overview

Next Generation Gene Therapeutics (NGGT) is a clinical-stage biotechnology company pioneering dual-functional vector gene therapies for genetic rare diseases. The company operates its proprietary 'One target, two bullets' technology platform, which uses dual-functional vectors to simultaneously silence harmful mutated genes and express correct protein versions. NGGT's product portfolio includes three clinical-stage gene therapy candidates: NGGT001 for Bietti's Crystalline Dystrophy (Phase I/II), NGGT002 for Phenylketonuria (Phase I/II), and NGGT006 for Familial Hypercholesterolemia (IND-enabling). The company maintains a 90,000-square-foot cGMP manufacturing facility for rAAV production.

Differentiator

Problem solved

Functional benefit

Products and services

  • NGGT001 Investigational AAV2-based gene therapy for Bietti's Crystalline Dystrophy (BCD), a rare autosomal recessive ocular disease caused by CYP4V2 gene mutations, currently in Phase I/II clinical trial. Designed for patients with BCD for whom no approved treatments exist.
  • NGGT002 Investigational gene therapy for Phenylketonuria (PKU), a rare genetic metabolic disorder caused by deficiency in phenylalanine hydroxylase, currently in Phase I/II clinical trial with demonstrated sustained plasma phenylalanine reduction. Aims to offer a single-treatment alternative to lifelong dietary management.
  • NGGT006

Quantifiable outcome

  • Visual acuity improved by 12.8 ± 3.7 ETDRS letters at 9 months in BCD patients (P = .0026)
  • +3 more outcomes

Companies that use Next Generation Gene Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Next Generation Gene Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Next Generation Gene Therapeutics partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Next Generation Gene Therapeutics competitors and assessment

Company assessment

Emerging players

  • Genprex: Clinical-stage gene therapy company developing treatments for cancer and diabetes using novel delivery systems. Comparable as a small clinical-stage biotech in gene therapy, though focused on different indications.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biotech with a commercialized AAV gene therapy (Roctavian for hemophilia A) and active programs in PKU and other inherited metabolic disorders. Comparable as a larger player in the same gene therapy + rare disease space.

Direct peers

  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based treatments for ocular and rare diseases. Comparable on AAV platform, ocular disease focus (overlap with NGGT001 BCD), and clinical-stage status.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for neurological and rare diseases using proprietary capsid engineering. Comparable on AAV platform and clinical-stage pipeline.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for rare genetic diseases. Comparable on AAV vector platform and clinical-stage status targeting rare monogenic disorders.
  • REGENXBIO: Clinical-stage gene therapy company using proprietary AAV vectors (NAV Technology Platform) to treat rare diseases including metabolic and ocular disorders. Most directly comparable to NGGT on AAV platform technology and rare disease focus.
  • uniQure: Gene therapy company developing AAV-based treatments for rare diseases including Huntington's disease and hemophilia. Comparable on AAV platform, rare disease strategy, and clinical-stage gene therapy pipeline.
  • MeiraGTx Holdings: Clinical-stage gene therapy company developing AAV-based treatments for rare diseases including ocular and metabolic disorders. Comparable platform technology and rare disease therapeutic focus.
  • Krystal Biotech: Commercial-stage gene therapy company with FDA-approved Vyjuvek for dystrophic epidermolysis bullosa, using a topical redosable gene therapy platform. Comparable on rare disease gene therapy focus and integrated manufacturing.

Regional players

  • Terns Pharmaceuticals: China-headquartered clinical-stage biotech with a pipeline spanning oncology and rare diseases, including gene therapy programs. Comparable as a similarly-staged China-US biotech with rare disease ambitions.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Next Generation Gene Therapeutics social profiles

Digital presence

Next Generation Gene Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Next Generation Gene Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Next Generation Gene Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Next Generation Gene Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next Generation Gene Therapeutics

What does Next Generation Gene Therapeutics do?

Next Generation Gene Therapeutics (NGGT) is a clinical-stage biotechnology company that discovers, develops, and manufactures investigational recombinant adeno-associated virus (rAAV) gene therapies for rare genetic diseases, using its proprietary dual-functional vector platform. Its current pipeline consists of three investigational gene therapy drug products — NGGT001 for Bietti's Crystalline Dystrophy, NGGT002 for Phenylketonuria, and NGGT006 for Familial Hypercholesterolemia — produced at its 90,000-square-foot cGMP facility in Suzhou, China. NGGT is pre-commercial and monetizes through future product sales, licensing, and pharmaceutical partnerships.

Is Next Generation Gene Therapeutics a public or private company?

Next Generation Gene Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Next Generation Gene Therapeutics founded?

Next Generation Gene Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Next Generation Gene Therapeutics based?

Next Generation Gene Therapeutics is headquartered in Walnut Creek, United States, in the North America region.

How does Next Generation Gene Therapeutics make money?

Two revenue lines are on record. Gene Therapy Product Revenue is the primary driver. The others are licensing and Partnership Revenue.

Who are Next Generation Gene Therapeutics's main competitors?

Genprex is listed as an emerging player. BioMarin Pharmaceutical is listed as a broad incumbent. Direct peers are Adverum Biotechnologies, Voyager Therapeutics, Solid Biosciences, REGENXBIO, uniQure, MeiraGTx Holdings and Krystal Biotech. Terns Pharmaceuticals is listed as a regional player.

Does Next Generation Gene Therapeutics have an API?

No public API is recorded for Next Generation Gene Therapeutics.

What industry is Next Generation Gene Therapeutics in?

Next Generation Gene Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAK, Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales